arsenic trioxide has been researched along with Disease Exacerbation in 20 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 11 (55.00) | 29.6817 |
| 2010's | 9 (45.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Imagawa, J | 1 |
| He, LJ; Jia, YL; Nan, X; Pei, XT; Wang, DX; Wang, HY; Xi, JF; Xu, YC; Yue, W; Zeng, Q; Zhang, B; Zhou, JN | 1 |
| Alfonso, V; Arcese, W; Baer, C; Cicconi, L; Del Principe, MI; Divona, M; Falconi, G; Ferrantini, A; Forghieri, F; Haferlach, T; Iaccarino, L; Lavorgna, S; Lo-Coco, F; Ottone, T; Travaglini, S; Usai, M; Venditti, A; Voso, MT | 1 |
| Canesastraro, M; Di Raimondo, F; Galimberti, S; Nagy, B; Palumbo, G; Petrini, M; Savlı, H; Sünnetçi, D | 1 |
| Fukami, T; Fukuda, M; Hojo, M; Inubushi, T; Miyamoto, S; Muraki, K; Nozaki, K; Onishi, N; Saiki, M; Satow, T; Saya, H; Shiino, A; Tanigaki, K; Yamada, S; Yoshimura, Y | 1 |
| Hu, L; Huang, L; Li, C; Meng, F; Tang, Y; Wan, K; Wang, Y; Xu, D; Zhou, J | 1 |
| Bonora, M; Gafà, R; Giorgi, C; Kroemer, G; Lanza, G; Magri, E; Missiroli, S; Pandolfi, PP; Patergnani, S; Perrone, M; Pinton, P; Poletti, F; Raimondi, A; Tacchetti, C | 1 |
| Alimoghaddam, K; Ghaffari, SH; Ghavamzadeh, A; Jamialahmadi, AH; Shayan-Asl, N | 1 |
| Schiffer, CA; Srinivasan, S | 1 |
| Borghi, M; Castellani, P; Ceccarelli, J; Delfino, L; Ferrini, S; Rubartelli, A; Tosetti, F; Zappia, E | 1 |
| Crocker, IR; Curran, WJ; McDonald, MW; Shu, HK | 1 |
| Chen, Q; Hao, XZ; Liu, JW; Qin, SK; Qu, FL; Qu, T; Sui, GJ; Sun, Y; Zhang, HP | 1 |
| Motzer, RJ; Schwartz, L; Vuky, J; Yu, R | 1 |
| Boehlke, L; Frater, JL; Nabhan, C; Parmar, S; Raji, A; Riley, M; Rundhaugen, LM; Tallman, MS | 1 |
| Berenson, JR; Ferretti, D; Purner, MB; Swift, RA | 1 |
| Cardinale, G; Gervasi, F; Pagnucco, G | 1 |
| Alimoghaddam, K; Ghavamzadeh, A; Jahani, M; Rostami, S; Sanaat, Z; Shariftabrizi, A; Tavangar, M; Tavangar, SM | 1 |
| Beer, TM; Crawford, ED; Dreicer, R; Margolin, KA; Nichols, CR; Quinn, DI; Raghavan, D; Stephenson, WT; Tangen, CM | 1 |
| Cui, X; Liu, T; Meng, WT; Xi, YM; Ye, XS | 1 |
| Aoki, M; Hara, S; Ishitsuka, K; Ogata, K; Suzumiya, J; Tamura, K | 1 |
3 review(s) available for arsenic trioxide and Disease Exacerbation
| Article | Year |
|---|---|
Acute promyelocytic leukemia with cryptic t(15;17) on isochromosome 17: a case report and review of literature.
Topics: Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Bone Marrow Examination; Chromosomes, Human, Pair 15; Chromosomes, Human, Pair 17; Disease Progression; Fatal Outcome; Genetic Predisposition to Disease; Humans; In Situ Hybridization, Fluorescence; Isochromosomes; Karyotype; Leukemia, Promyelocytic, Acute; Male; Molecular Diagnostic Techniques; Mutation; Oncogene Proteins, Fusion; Oxides; Phenotype; Predictive Value of Tests; Time Factors; Translocation, Genetic; Treatment Outcome; Tretinoin; Young Adult | 2015 |
Current treatment options and strategies for myelodysplastic syndromes.
Topics: Age Factors; Antimetabolites, Antineoplastic; Arsenic Trioxide; Arsenicals; Blood Transfusion; Clinical Trials as Topic; Comorbidity; Disease Progression; Erythropoietin; Farnesyltranstransferase; Hematinics; Histone Deacetylase Inhibitors; Humans; Immunologic Factors; Myelodysplastic Syndromes; Oxides; Recombinant Proteins; Social Class; Stem Cell Transplantation | 2008 |
Targeting multiple myeloma cells and their bone marrow microenvironment.
Topics: Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Bone Marrow Cells; Boronic Acids; Bortezomib; Cell Adhesion; Cytokines; Disease Progression; Disease-Free Survival; Humans; Ligands; Multiple Myeloma; Neovascularization, Pathologic; Oxides; Protease Inhibitors; Pyrazines; Signal Transduction; Thalidomide | 2004 |
7 trial(s) available for arsenic trioxide and Disease Exacerbation
| Article | Year |
|---|---|
[Multicenter phase II clinical trial of arsenic trioxide injection in the treatment of primary hepatocarcinoma].
Topics: Adult; Aged; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Carcinoma, Hepatocellular; Disease Progression; Female; Follow-Up Studies; Half-Life; Humans; Injections; Leukopenia; Liver Neoplasms; Lung Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Nausea; Neoplasm Staging; Oxides; Quality of Life; Remission Induction; Survival Rate; Vomiting | 2011 |
Phase II trial of arsenic trioxide in patients with metastatic renal cell carcinoma.
Topics: Adult; Aged; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Carcinoma, Renal Cell; Disease Progression; Female; Humans; Karnofsky Performance Status; Kidney Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Oxides; Tomography, X-Ray Computed | 2002 |
Phase II trial of arsenic trioxide in relapsed and refractory acute myeloid leukemia, secondary leukemia and/or newly diagnosed patients at least 65 years old.
Topics: Acute Disease; Aged; Aged, 80 and over; Arsenic Trioxide; Arsenicals; ATP Binding Cassette Transporter, Subfamily B; Bone Marrow Examination; Disease Progression; Drug Resistance, Multiple; Female; Glycoproteins; Humans; Leukemia, Myeloid; Male; Middle Aged; Neoplasms, Second Primary; Oxides; Salvage Therapy; Treatment Outcome | 2004 |
A prospective, open-label safety and efficacy study of combination treatment with melphalan, arsenic trioxide, and ascorbic acid in patients with relapsed or refractory multiple myeloma.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Ascorbic Acid; Disease Progression; Drug Resistance, Neoplasm; Humans; Melphalan; Middle Aged; Multiple Myeloma; Oxides; Prospective Studies; Recurrence; Time Factors; Treatment Outcome | 2004 |
Anti-leukemic and anti-angiogenesis efficacy of arsenic trioxide in new cases of acute promyelocytic leukemia.
Topics: Adolescent; Adult; Angiogenesis Inhibitors; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Bone Marrow; Disease Progression; Female; Follow-Up Studies; Humans; Immunohistochemistry; Leukemia, Promyelocytic, Acute; Leukocytosis; Male; Middle Aged; Neovascularization, Pathologic; Oxides; Recurrence; Remission Induction; Survival Rate; Time Factors; Treatment Outcome | 2006 |
Southwest Oncology Group phase II study of arsenic trioxide in patients with refractory germ cell malignancies.
Topics: Adult; Antineoplastic Agents; Arrhythmias, Cardiac; Arsenic Trioxide; Arsenicals; Disease Progression; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Humans; Male; Middle Aged; Neoplasms, Germ Cell and Embryonal; Oxides; Pneumonia; Respiratory Distress Syndrome; Survival Rate; Testicular Neoplasms; Treatment Outcome | 2006 |
Therapeutic potential of arsenic trioxide with or without interferon-alpha for relapsed/refractory adult T-cell leukemia/lymphoma.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Cell Line, Tumor; Disease Progression; Female; Humans; Interferon-alpha; Leukemia-Lymphoma, Adult T-Cell; Male; Oxides; Recurrence; Salvage Therapy; Thrombocytopenia | 2007 |
10 other study(ies) available for arsenic trioxide and Disease Exacerbation
| Article | Year |
|---|---|
Switching from all-trans retinoic acid to arsenic trioxide for newly diagnosed acute promyelocytic leukemia.
Topics: Adult; Aged; Antineoplastic Agents; Arsenic Trioxide; Disease Progression; Disseminated Intravascular Coagulation; Drug Substitution; Humans; Leukemia, Promyelocytic, Acute; Male; Treatment Outcome; Tretinoin | 2018 |
Arsenic trioxide inhibits liver cancer stem cells and metastasis by targeting SRF/MCM7 complex.
Topics: Animals; Antineoplastic Agents; Arsenic Trioxide; Carcinoma, Hepatocellular; Cell Line, Tumor; Disease Progression; Down-Regulation; Gene Expression Regulation, Neoplastic; Gene Ontology; Humans; Liver Neoplasms; Liver Neoplasms, Experimental; Lung Neoplasms; Male; Mice; Mice, Inbred NOD; Mice, Nude; Mice, SCID; Minichromosome Maintenance Complex Component 7; Neoplastic Stem Cells; Prognosis; Serum Response Factor; Transplantation, Heterologous | 2019 |
Mutational landscape of patients with acute promyelocytic leukemia at diagnosis and relapse.
Topics: Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Bone Marrow; Clone Cells; Disease Progression; Drug Resistance, Neoplasm; High-Throughput Nucleotide Sequencing; Humans; Leukemia, Promyelocytic, Acute; Mutation; Neoplasm Proteins; Neoplastic Stem Cells; Oncogene Proteins, Fusion; Promyelocytic Leukemia Protein; Protein Domains; Recurrence; Remission Induction; Reproducibility of Results; Retinoic Acid Receptor alpha; RNA, Messenger; RNA, Neoplasm; Tretinoin | 2019 |
Bortezomib and Arsenic Trioxide Activity on a Myelodysplastic Cell Line (P39): A Gene Expression Study.
Topics: Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Bortezomib; Cell Cycle Checkpoints; Cell Line, Tumor; Disease Progression; Drug Synergism; Estradiol; Gene Expression Regulation, Leukemic; Gene Regulatory Networks; Humans; Leukemia, Myelomonocytic, Chronic; Neoplasm Proteins; NF-kappa B; Oxides; Proteasome Inhibitors; Signal Transduction | 2015 |
Arsenic trioxide sensitizes glioblastoma to a myc inhibitor.
Topics: Aged; Animals; Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Brain Neoplasms; Cell Differentiation; Cell Proliferation; Disease Progression; ErbB Receptors; Female; Glioblastoma; Hedgehog Proteins; Humans; Magnetic Resonance Imaging; Male; Mice, SCID; Middle Aged; Neoplastic Stem Cells; Oxides; Proto-Oncogene Proteins c-myc; Signal Transduction; Thiazoles; Xenograft Model Antitumor Assays | 2015 |
PML at Mitochondria-Associated Membranes Is Critical for the Repression of Autophagy and Cancer Development.
Topics: Adenine; Animals; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Autophagy; Calcium; Cell Line, Tumor; Disease Progression; Fibroblasts; Gene Expression Regulation, Neoplastic; Humans; Leukemia, Promyelocytic, Acute; Membrane Potential, Mitochondrial; Mice; Mice, Knockout; Mitochondria; Mitochondrial Membranes; Oncogene Proteins, Fusion; Oxides; Promyelocytic Leukemia Protein; Signal Transduction; Tumor Suppressor Protein p53; Xenograft Model Antitumor Assays | 2016 |
Telomerase activity and telomere length in patients with acute promyelocytic leukemia: indicative of proliferative activity, disease progression, and overall survival.
Topics: Adolescent; Adult; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Cell Growth Processes; Disease Progression; Enzyme Activation; Female; Humans; Leukemia, Promyelocytic, Acute; Male; Middle Aged; Oncogene Proteins, Fusion; Oxides; Survival Rate; Telomerase; Telomere | 2008 |
The redox state of the lung cancer microenvironment depends on the levels of thioredoxin expressed by tumor cells and affects tumor progression and response to prooxidants.
Topics: Animals; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Carcinoma, Non-Small-Cell Lung; Cysteine; Disease Progression; Glutathione; HCT116 Cells; Humans; Intramolecular Oxidoreductases; Jurkat Cells; Lung Neoplasms; Macrophage Migration-Inhibitory Factors; Mice; Mice, SCID; Oxidation-Reduction; Oxides; Sulfhydryl Compounds; Thioredoxins | 2008 |
Pattern of failure after limited margin radiotherapy and temozolomide for glioblastoma.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease Progression; Disease-Free Survival; Dose Fractionation, Radiation; Female; Follow-Up Studies; Glioblastoma; Humans; Magnetic Resonance Imaging; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Oxides; Radiotherapy Planning, Computer-Assisted; Temozolomide; Tomography, X-Ray Computed; Treatment Failure; Tumor Burden; Young Adult | 2011 |
[Methylation of P15INK4B gene in patients with myelodysplastic syndromes and demethylating effects of drugs].
Topics: Arsenic Trioxide; Arsenicals; Azacitidine; Cyclin-Dependent Kinase Inhibitor p15; Decitabine; Disease Progression; DNA Methylation; Genetic Predisposition to Disease; Humans; Leukemia; Myelodysplastic Syndromes; Oxides | 2007 |